mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations

doi:10.1016/j.vaccine.2022.08.024

PMC full text:

Vaccine. 2022 Oct 6; 40(42): 6114–6124.

Published online 2022 Sep 15. doi: 10.1016/j.vaccine.2022.08.024

Copyright/LicenseRequest permission to reuse: Copyright © 2022 Published by Elsevier Ltd.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

<< PrevFig. 4Next >>

Fig. 4

An external file that holds a picture, illustration, etc.
Object name is gr4_lrg.jpg

Open in a separate window

Levels of IgM and IgE antibodies against PEG and specificity of anti-PEG ELISA. Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees collected at baseline (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups), 18.9 days (arithmetic mean ± 2.4 SD) after the prime (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups) and 19.3 days (arithmetic mean ± 3.9 SD) after the boost (n = 10 for BNT162b2 and n = 10 for mRNA-1273 groups), were tested for IgM (A and B) or IgE (C and D) antibodies against PEGylated BSA 20 kDa or against bovine serum albumin (BSA, E and F).

Fig. 4

Images in this article

Click on the image to see a larger version.